MOTS-c

What it is

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid peptide encoded inside mitochondrial DNA, described in 2015. It belongs to a small class of “mitochondrial-derived peptides” that appear to act as signaling molecules between the mitochondria and the rest of the cell. The underlying biology is legitimate and actively researched — but the compound sold online as a “research peptide” is a long way from an established human therapy.

What it’s approved or studied for

Nothing is approved. MOTS-c is not an approved drug in any jurisdiction and is sold for laboratory research only. In the scientific literature it is studied mainly as a probe of mitochondrial and metabolic biology: insulin sensitivity, exercise adaptation, and aging pathways in cells and animals.

What human evidence exists

Essentially none of the controlled kind. The headline findings — better insulin sensitivity, reduced diet-induced obesity, improved exercise capacity in aged mice — are Grade D preclinical evidence from cell and rodent studies. Endogenous MOTS-c has been measured in humans and tracks with exercise, which is interesting biology, but that is an observation, not evidence that injecting MOTS-c produces a benefit. No adequate, controlled human trials establish that supplemental MOTS-c improves any clinical outcome.

The major unknowns

Human pharmacokinetics, an effective or safe dose, and whether any rodent metabolic benefit translates to people are all open. Whether it does anything for human aging or “longevity” — the reason it is marketed — is unknown (Grade U). As with all research-chemical peptides, product identity and purity are uncontrolled, so what is in a given vial is uncertain.

Most important safety considerations

There is no controlled human safety data, so the honest answer to “is it safe?” is that no one knows, and long-term risk is unstudied. Product quality is unregulated. This page summarizes the research record; it is not medical advice or an endorsement of use.